H. Jack West, MD

Articles

Dr. West on FDA Approval of Brigatinib in ALK+ NSCLC

May 2nd 2017

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of brigatinib (Alunbrig) as a treatment for patients with metastatic ALK-positive non–small cell lung cancer (NSCLC) who are resistant to prior crizotinib (Xalkori).

Dr. West on Considering Factors for EGFR TKIs in NSCLC

November 15th 2016

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses factors he takes into consideration for EGFR tyrosine kinase inhibitors in patients who have EGFR-positive non–small cell lung cancer (NSCLC).

Dr. West on Advancements for Patients With T790M-Mutant NSCLC

August 8th 2016

Howard L. (Jack) West, MD, medical oncologist, director, Thoracic Oncology Program, Swedish Cancer Institute, discusses recent advancements for patients with T790M-mutant non–small cell lung cancer.

Dr. West Talks About the Escalating Cost of Cancer Care

August 4th 2011

Dr. Jack West from the Swedish Cancer Institute Talks About the Escalating Cost of Cancer Care

Dr. West Discusses Anticipated Future Clinical Trials

August 1st 2011

Dr. Jack West from the Swedish Cancer Institute Talks About Anticipated Future Clinical Trials

Dr. West on 4 Important Upcoming Clinical Trial Results

July 28th 2011

Dr. Jack West from Swedish Cancer Institute Discusses 4 Important Upcoming Clinical Trials Results in Lung Cancer.

Dr. West Explains the Pemetrexed Clinical Trial

July 22nd 2011

Dr. Jack West from Swedish Cancer Institute Explains the Pemetrexed Clinical Trial

Dr. West on the Gefitinib Advanced NSCLC Trial

July 19th 2011

Dr. Jack West Swedish Cancer Institute on the Gefitinib Advanced non-small cell lung cancer Trial

Dr. West on NSCLC Afatinib and Cetuximab Combination

July 7th 2011

Dr. H. Jack West from Swedish Cancer Institute discusses Afatinib and Cetuximab Combination in NSCLC

Dr. West on ALK-NSCLC Crizotinib Survival Benefit

June 30th 2011

Dr. H. Jack West from Swedish Cancer Institute Discusses ALK-NSCLC Crizotinib Survival Benefit

Dr. West Discusses Crizotinib in ALK-NSCLC Trial Results

June 23rd 2011

Dr. Jack West from the Swedish Cancer Institute Discusses Crizotinib in ALK-NSCLC Trial Results

West's Points: Evolving Issues With ALK Rearrangements

June 3rd 2010

H. Jack West, MD, takes a moment to talk about what he is finding in regard to anaplastic lymphoma kinase (ALK) rearrangements seen in approximately 4% of patients with nonÃƒÂ¢Ã¯Â¿Â½Ã¯Â¿Â½small cell lung cancer, as reviewed by Shaw et al in a September 2009 issue of the Journal of Clinical Oncology.